COVID-19 vaccine: China grants first patent to CanSino
CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries
- Aug 17, 2020,
- Updated Aug 17, 2020 10:34 AM IST
China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday.
The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug. 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino's Hong Kong shares rose around 14% in Monday's morning session. Its Shanghai shares rose by 6.6% as of midday.
Also read: COVID-19 vaccine: Britain urges at-risk groups to sign up for trials
China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday.
The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug. 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino's Hong Kong shares rose around 14% in Monday's morning session. Its Shanghai shares rose by 6.6% as of midday.
Also read: COVID-19 vaccine: Britain urges at-risk groups to sign up for trials